Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.

@article{Lee2012CosteffectivenessOF,
  title={Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.},
  author={Soyon Lee and Daniel C Baxter and Brendan L. Limone and Matthew Steven Roberts and Craig I Coleman},
  journal={Journal of medical economics},
  year={2012},
  volume={15 6},
  pages={1088-96}
}
OBJECTIVE Fingolimod has been shown to be more efficacious than interferon (IFN) beta-1a, but at a higher drug acquisition cost. The aim of this study was to assess the cost-effectiveness of fingolimod compared to IFN beta-1a in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) in the US. METHODS A Markov model comparing fingolimod to intramuscular IFN beta-1a using a US societal perspective and a 10-year time horizon was developed. A cohort of 37-year-old patients with… CONTINUE READING